Biocryst Pharmaceuticals (BCRX) Non Operating Income (2024 - 2026)

Biocryst Pharmaceuticals' Non Operating Income history runs 3 years deep, the most recent figure standing at -$19.2 million for Q1 2026.

• Quarterly Non Operating Income rose 6.15% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$72.3 million (up 14.24% YoY) and the FY2025 annual result came in at -$73.6 million, up 12.81% from the prior year.
• Non Operating Income was -$19.2 million for Q1 2026 at Biocryst Pharmaceuticals, down from -$12.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$12.4 million in Q4 2025 and bottomed at -$23.3 million in Q2 2025.
• A 3-year average of -$19.7 million and a median of -$20.5 million in 2024 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 42.43% in 2025, while the deepest fall reached 9.58% in 2025.
• Biocryst Pharmaceuticals' Non Operating Income stood at -$21.5 million in 2024, then surged by 42.43% to -$12.4 million in 2025, then sank by 55.32% to -$19.2 million in 2026.
• Business Quant data shows BCRX's Non Operating Income at -$19.2 million in Q1 2026, -$12.4 million in Q4 2025, and -$17.5 million in Q3 2025.